Clinical Trial

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2023-01-19; most recent amendment 2025-08-27.
Status change: Recruiting → Active, Not Recruiting 2024-11-13
Trial Details
NCT Number NCT05704244
Lead Sponsor Ferring Pharmaceuticals
Conditions Bladder Cancer
Enrollment 25 participants
Start Date 2022-12-21
Primary Completion 2029-11-30 (estimated)
Study Completion 2029-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-28